Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Analysis Reveals Detailed Structural Features of Amyloid Oligomers

By BiotechDaily International staff writers
Posted on 15 Jul 2013
Image: Molecular structures of amyloid oligomers and amyloid fibers (Photo courtesy of the University of California, Los Angeles).
Image: Molecular structures of amyloid oligomers and amyloid fibers (Photo courtesy of the University of California, Los Angeles).
Advanced analytical analysis of amyloid-beta42 oligomers has yielded insights into the structure of these oligomers that helps to explain the mechanism behind the process of oligomerization and the reasons for their molecular toxicity.

Oligomerization of the 42 amino acid peptide amyloid-beta42 plays a key role in the pathogenesis of Alzheimer disease, but despite great academic and medical interest, the structure of these oligomers has not been well characterized.

In the current study, investigators at the University of California, Los Angeles (USA) employed several advanced analytical techniques to delve the secrets of the oligomeric (globulomeric) form of amyloid-beta42. They reported in the June 28, 2013, issue of the Journal of Biological Chemistry that transmission electron microscopy showed amyloid-beta42 oligomers were globular structures with diameters of about seven to eight nanometers. Circular dichroism revealed primarily beta-structures, while X-ray powder diffraction suggested a highly ordered intrasheet hydrogen-bonding network with heterogeneous intersheet packing. Residue-level mobility analysis on spin labels introduced at 14 different positions showed a structured state but with a disordered state at all labeling sites. Side chain mobility analysis suggested that structural order increased from N- to C-terminal regions. Intermolecular distance measurements at 14 residue positions suggested that C-terminal residues glycine-29 to valine-40 formed a tightly packed core with intermolecular distances in a narrow range of 1.15–1.25 nm.

The authors suggested that the significant structural and organizational differences that distinguished amyloid-beta42 globulomers from the free peptide and amyloid-plaque forms may help to explain the lack of success of experimental anti-Alzheimer's disease drugs that targeted amyloid plaques while ignoring the globulomeric form of the molecule.

Related Links:
University of California, Los Angeles



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.